

# Hyperglycemic hyperosmolar state

## CANADIAN PAEDIATRIC SURVEILLANCE PROGRAM

100-2305 St. Laurent Blvd.  
Ottawa, ON K1G 4J8  
Tel: 613-526-9397, ext. 239  
Fax: 613-526-3332  
cpsp@cps.ca  
www.cpsp.cps.ca

## REPORTING INFORMATION

(To be completed by the CPSP)

Report number: \_\_\_\_\_

Month of reporting: \_\_\_\_\_

Province: \_\_\_\_\_

Today's date: \_\_\_\_\_

Please complete the following sections for the case identified above. If the information asked for below is not readily available, please leave it blank. Strict confidentiality of information will be assured.

### CASE DEFINITION FOR HYPERGLYCEMIC HYPEROSMOLAR STATE

Report any patient less than 18 years of age (up to the 18th birthday), with or without a prior diagnosis of diabetes, presenting to hospital with hyperglycemic hyperosmolar state (HHS), defined as:

- Serum glucose concentration of >33 mmol/L
- Serum osmolality of >320 mOsm/kg (calculated or measured)
- Absence of significant acidosis:
  - Serum bicarbonate concentration of >15 mEq/L
  - Arterial/capillary pH of >7.30 or venous pH of >7.25

*This case definition is aligned with the current Diabetes Canada diagnostic criteria for HSS with one important amendment: ketosis is **NOT** an exclusion factor. The rationale for including ketosis is that the original HHS definition was based on adult presentation, and it is well demonstrated that more than 40% of children and adolescents with type 2 diabetes present with ketones (even if not acidotic).*

Month first seen: \_\_\_\_\_

### SECTION 1 – PATIENT DEMOGRAPHIC INFORMATION

1.1 Month and year of birth: \_\_\_\_\_ / \_\_\_\_\_  
MM YYYY

1.2 Sex assigned at birth:  Male  Female  Intersex  Unknown

1.3 Province/territory of residence: \_\_\_\_\_ 1.4 First 3 digits of current residence postal code: \_\_\_ \_\_ \_\_

1.5 Physician-reported population groups (select all that apply):

- |   |   |  |  |
|---|---|--|--|
| <input type="checkbox"/> Arab   | <input type="checkbox"/> Black  | <input type="checkbox"/> Chinese                               | <input type="checkbox"/> Filipino              |
| <input type="checkbox"/> Japanese   | <input type="checkbox"/> Korean   | <input type="checkbox"/> Latin American                        | <input type="checkbox"/> White                 |
| <input type="checkbox"/> First Nations  | <input type="checkbox"/> Inuit  | <input type="checkbox"/> Métis                                 | <input type="checkbox"/> Unknown               |
| <input type="checkbox"/> Southeast Asian<br>(e.g., Vietnamese,<br>Cambodian, Laotian) | <input type="checkbox"/> South Asian<br>(e.g., East Indian,<br>Pakistani, Sri Lankan) | <input type="checkbox"/> West Asian<br>(e.g., Iranian, Afghan) | <input type="checkbox"/> Other, specify: _____ |

### SECTION 2 – MEDICAL HISTORY OF PATIENT

2.1 Diabetes type:  Type 1 (T1D)  Type 2 (T2D)  Maturity-onset diabetes of the young (MODY)  
 Medication induced; specify: \_\_\_\_\_  Cystic fibrosis-related  Type not yet determined  
 Other; specify: \_\_\_\_\_

2.2 New diabetes diagnosis at time of presentation with HHS?  Yes  No  Unknown  
If No, patient's age at diabetes diagnosis: \_\_\_\_\_ years **OR** date of diagnosis: \_\_\_\_\_ / \_\_\_\_\_  Unknown  
MM YYYY

If Yes, has patient had prior screening for T1D or T2D?  Yes; approximate date: \_\_\_\_\_ / \_\_\_\_\_  No  Unknown  
MM YYYY

2.3 Comorbidities at time of presentation with HHS (select all that apply):

- Obesity (i.e., BMI-z score >95<sup>th</sup> percentile for age and sex)
- Hypertension (systolic blood pressure or diastolic blood pressure >95<sup>th</sup> percentile for age and height)
- Dyslipidemia (total cholesterol >5.2 mmol/L; LDL-C >3.4 mmol/L; HDL-C <1 mmol/L; non-HDL >3.8 mmol/L; triglycerides >1.5 mmol/L)
- Other, specify: \_\_\_\_\_
- None
- Unknown

- 2.4 Insulin prescribed prior to presentation to the reporting physician:  Yes, specify type: \_\_\_\_\_  No  
 If Yes, specify regimen:  Pump  Single daily injection  Twice daily (BID) injection  
 Three times daily (TID) injection  Multiple daily injections  None
- 2.5 Other diabetes medications on presentation to reporting physician:  Yes, specify: \_\_\_\_\_  No
- 2.6 Non-diabetic medications on presentation to reporting physician:  Yes, specify: \_\_\_\_\_  No
- 2.7 Family history of diabetes:  Yes  No  Unknown  
 If Yes, specify type and affected relative(s) (e.g., grandfather, mother): \_\_\_\_\_
- 2.8 Does the patient have access to clean, reliable drinking water?  Yes  No  Unknown

**SECTION 3 – CASE PRESENTATION**

- 3.1 Precipitating factors (select all that apply):  
 Non-adherence with medication, specify medication: \_\_\_\_\_  
 Infection, specify: \_\_\_\_\_  
 Ischaemic event, specify: \_\_\_\_\_  
 Trauma, specify: \_\_\_\_\_  
 Insulin administration issue (e.g., pump site failure), specify: \_\_\_\_\_  
 Dehydration, specify: \_\_\_\_\_  
 Recreational drug use, specify: \_\_\_\_\_  
 Other, specify: \_\_\_\_\_  
 Unprovoked  
 Unknown
- 3.2 Most current height: \_\_\_\_ cm (date: \_\_\_\_ / \_\_\_\_ / \_\_\_\_ ) and most current weight: \_\_\_\_ kg (date: \_\_\_\_ / \_\_\_\_ / \_\_\_\_ )  
MM      YYYY MM      YYYY
- 3.3 Vital signs at presentation to your medical centre:  
 Blood pressure: \_\_\_\_ / \_\_\_\_ mmHg      Heart rate: \_\_\_\_ bpm      Respiratory rate: \_\_\_\_  
 Temperature: \_\_\_\_ °C      Glasgow Coma Scale (GCS): \_\_\_\_ / 15
- 3.4 Signs and symptoms at presentation to your medical centre (select all that apply):  
 Acanthosis nigricans       Polydipsia       Polyuria       Weight loss  
 Nausea/vomiting       Malaise/weakness       Circulatory shock       Dry mouth/tongue  
 Visual acuity changes       Headache       Altered level of consciousness  
 Seizure       None       Other, specify: \_\_\_\_\_
- 3.5 Investigations at presentation to your medical centre (as available):

Parameter	Value			Units	
	<input type="radio"/> Arterial: ____	<input type="radio"/> Venous: ____	<input type="radio"/> Capillary: ____		
pH					
Serum glucose				mmol/L	
Serum ketones				mmol/L	
Capillary ketones				mmol/L	
Serum lactate				mmol/L	
Serum β-hydroxybutyrate				mmol/L	
Serum urea				mmol/L	
Serum osmolality				mOsm/kg	
Serum bicarbonate				mEq/L	
Serum sodium (measured)				mEq/L	
Serum potassium				mEq/L	
Serum phosphate				mEq/L	
Serum magnesium				mEq/L	
Serum calcium				mEq/L	
Serum creatinine				µmol/L	
White blood cells	White blood count: ____	Neutrophils: ____		×10 <sup>9</sup> cells/L	
Creatinine kinase				U/L	
Urine ketones				mmol/L	
Urine dipstick ketones	<input type="radio"/> Trace	<input type="radio"/> Mild	<input type="radio"/> Moderate	<input type="radio"/> Large	<input type="radio"/> Very Large

**SECTION 4 – HOSPITAL COURSE**

- 4.1 Date of presentation with HHS to first point of care: \_\_\_\_ / \_\_\_\_ / \_\_\_\_  
DD MM YYYY
- 4.2 Presentation acuity and interval to therapy:
- 4.2.1 Days of illness prior to presentation at first point of care: \_\_\_\_\_ days
- 4.2.2 First point of care:  Nurse practitioner-run primary care centre  Family medicine primary care centre  
 Paediatric primary care centre  Community hospital  Tertiary care centre
- 4.2.3 Approximate distance/time travelled to first point of care: \_\_\_\_ km / \_\_\_\_ hours  Unknown
- 4.2.4 Approximate distance/time travelled from first point of care to tertiary hospital:  
\_\_\_\_ km / \_\_\_\_ hours  Unknown
- 4.2.5 Time from first presentation to commencement of therapy (e.g., IV fluid initiation):  
\_\_\_\_ hours, \_\_\_\_ minutes  Unknown
- 4.2.6 Mode of transfer to tertiary hospital:  Land ambulance  Air ambulance  Not applicable
- 4.2.7 Highest level of care:  Emergency department  Community hospital paediatric ward  Endocrine ward  
 Tertiary hospital paediatric ward  Paediatric intensive care unit  Other, specify: \_\_\_\_\_
- 4.3 Hospital length of stay: \_\_\_\_ days
- 4.4 Interventions (select all that apply):
- IV fluid initial bolus; specify volume: \_\_\_\_ mL/kg  
Type:  0.9 sodium chloride (NaCl)  0.45 NaCl  Ringer's lactate  Colloid  Other, specify: \_\_\_\_\_
- IV fluid in first 24 hours; specify total volume: \_\_\_\_ L  
Type:  0.9 NaCl  0.45 NaCl  Ringer's lactate  Colloid  Other, specify: \_\_\_\_\_
- IV insulin; specify rate: \_\_\_\_ U/kg/hour
- IV bicarbonate
- IV potassium
- Thromboprophylaxis
- None
- 4.5 Complications (select all that apply):
- Hyperkalemia; specify maximum value: \_\_\_\_ mEq/L
- Hypokalemia; specify minimum value: \_\_\_\_ mEq/L
- Cerebral edema; confirmed via:  
 Computerized tomography  Magnetic resonance imaging  Clinical diagnosis; specify GCS: \_\_\_\_\_
- Rhabdomyolysis; maximum creatinine kinase: \_\_\_\_ U/L
- Malignant hyperthermia-like syndrome; maximum temperature: \_\_\_\_ °C
- Hypoglycemia; minimum serum glucose: \_\_\_\_ mmol/L
- Thrombo-ischaeamic event(s); specify: \_\_\_\_\_
- Impaired renal function; maximum serum creatinine: \_\_\_\_ μmol/L
- Death
- Other, specify: \_\_\_\_\_
- None
- 4.6 Insulin at discharge:  Pump  Daily injection  BID injection; specify insulin type: \_\_\_\_\_  
 TID injection; specify insulin type: \_\_\_\_\_  Premixed insulin  None
- 4.7 Other diabetes medications at discharge:  Yes, specify: \_\_\_\_\_  None

**SECTION 5 – ADDITIONAL INFORMATION**

- 5.1 Are you willing to be contacted by the Canadian Paediatric Surveillance Program (CPSP) for further information on this questionnaire?  Yes  No

**SECTION 6 – REPORTING PHYSICIAN**

- 6.1 Which of the following best describes your practice?
- General paediatrician; specify:  Primary care practice  Community hospital  Tertiary care hospital
- Paediatric emergency physician
- Paediatric endocrinologist
- Paediatric intensivist
- Other, specify: \_\_\_\_\_

First name \_\_\_\_\_ Surname \_\_\_\_\_  
Address \_\_\_\_\_  
City \_\_\_\_\_ Province \_\_\_\_\_ Postal code \_\_\_\_\_  
Telephone number \_\_\_\_\_ Fax number \_\_\_\_\_  
E-mail \_\_\_\_\_ Date completed \_\_\_\_\_

**Thank you for completing this form**

(HHS 06/2023)